SCHEMBL12226505

SCHEMBL12226505

CC(=O)CN1CCCNCC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.53
CHRM3 P20309 2/20 0.53
SIGMAR1 Q99720 5/20 0.53
CXCR4 P61073 9/20 0.47
MEN1 O00255 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
ADRA2C P18825 1/20 0.42
CCR2 P41597 1/20 0.42
CXCL12 P48061 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.36
CA2 P00918 1/20 0.36
CHKA P35790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16800789 0.93 SIGMAR1 (0.48) CHRM5CHRM3SIGMAR1CXCR4MEN1
SCHEMBL8038 0.92 CHRM5 (0.55) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL24247411 0.92 CHRM5 (0.55) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL16800794 0.91 SIGMAR1 (0.47) CHRM5CHRM3SIGMAR1CXCR4MEN1
Hydrochloric Acid SCHEMBL3925566 0.90 CHRM5 (0.53) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL13742551 0.90 CHRM5 (0.53) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL16800550 0.87 SIGMAR1 (0.44) CHRM5CHRM3SIGMAR1CXCR4MEN1
SCHEMBL11952843 0.84 SIGMAR1 (0.39) CHRM5CHRM3SIGMAR1CXCR4MEN1
SCHEMBL29299503 0.84 CHRM5 (0.49) CHRM5CHRM3SIGMAR1MEN1KMT2A
SCHEMBL28170665 0.83 CXCR4 (0.50) CHRM5CHRM3SIGMAR1CXCR4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044206-B2 Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl ASTELLAS PHARMA INC. (JP) 2011-10-25 US disclosed
US-8044206-B2 Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl ASTELLAS PHARMA INC. (JP) 2011-10-25 US disclosed
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. 2007-05-03 US disclosed
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl SCN1B, CACNA1B, SCN2A CHRM5 3130/4885CHRM3 2459/4885SIGMAR1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.